Intraoperative nociception and postoperative inflammation associated with the suppression of major complications due to thoracic epidural block after pleurectomy/decortication for malignant pleural mesothelioma under general anesthesia: A retrospective observational study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
01 Sep 2023
01 Sep 2023
Historique:
medline:
4
9
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
A recent study showed that thoracic epidural block (TEB) suppressed the occurrence of major complications after pleurectomy/decortication (P/D) for malignant pleural mesothelioma (MPM) under general anesthesia. To investigate the mechanisms underlying the correlation, both acute inflammatory status and intraoperative nociception were evaluated in the present study. In a single-institutional observational study, consecutive adult patients undergoing P/D were enrolled from March 2019 to April 2022. Perioperative acute inflammatory status was evaluated using differential White blood cell (WBC) counts and serum concentration of C-reactive protein (CRP) both before and after the surgery on postoperative day (POD) 1. The averaged value of nociceptive response index during surgery (mean NR) was obtained to evaluate the level of intraoperative nociception. Multivariable logistic regression analysis was performed to determine the association between perioperative variables and major complications Postoperative major postoperative complication was defined as Clavien-Dindo grades ≥ III. We conducted this study with 97 patients. After logistic regression analysis showed that general anesthesia without TEB was a sole risk factor for major complications, patients were divided into 2 groups: general anesthesia with and without TEB. The incidence of major complications was significantly lower in patients with TEB (33.3%, n = 33) than in those without TEB (64.1%, n = 64, P < .01). Although there was no significant difference in the CRP level between 2 groups, the lymphocyte-to-monocyte ratio (LMR) on POD 1 in patients with TEB was significantly higher than that in patients without TEB (P = .04). The mean NR was significantly lower in patients with TEB than that in those without TEB (P = .02). Both lower mean NR during surgery and higher LMR on POD 1 are likely associated the suppression of major complications due to TEB after P/D under general anesthesia. Decreases in the postoperative acute inflammatory response, caused by the reduction of intraoperative nociception due to TEB, may help suppress major complications after P/D.
Identifiants
pubmed: 37657017
doi: 10.1097/MD.0000000000034832
pii: 00005792-202309010-00022
pmc: PMC10476709
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e34832Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Munetaka Hirose is an inventor on a patent application for the equation of the nociceptive response (NR) index, which was registered on August 25, 2021 (Japanese Patent No. 6934251). Philips Japan Co. Ltd. (Tokyo, Japan) installed the equation on the ORSYS anesthesia information management system, but as of yet no commercial activity has occurred. This was included in the disclosure of conflict of interests to patients.
Références
Int J Gen Med. 2021 Aug 12;14:4459-4468
pubmed: 34408483
Ann Surg. 2012 Aug;256(2):357-62
pubmed: 22750759
Med Sci Monit. 2018 May 20;24:3324-3331
pubmed: 29779036
Pharmacol Rev. 2000 Dec;52(4):595-638
pubmed: 11121511
J Clin Med. 2021 Oct 26;10(21):
pubmed: 34768488
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Anesth Analg. 2015 Oct;121(4):1011-1029
pubmed: 25390276
Reg Anesth Pain Med. 2022 Aug;47(8):494-499
pubmed: 35618297
Exp Hematol. 2022 Aug-Sep;112-113:44-59.e6
pubmed: 35907584
Eur J Anaesthesiol. 2021 Dec 1;38(12):1215-1222
pubmed: 33831900
Int J Clin Oncol. 2020 Apr;25(4):633-640
pubmed: 31781993
Front Immunol. 2018 Jun 12;9:1351
pubmed: 29946323
J Clin Monit Comput. 2021 May;35(3):499-503
pubmed: 32146603
J Clin Med. 2022 Oct 14;11(20):
pubmed: 36294399
Ann Surg Oncol. 2021 Jun;28(6):3057-3065
pubmed: 33123856
Biomark Med. 2019 Oct;13(15):1263-1272
pubmed: 31584289
Ann Thorac Surg. 2022 Apr;113(4):1348-1353
pubmed: 33930356
Sci Rep. 2020 Sep 17;10(1):15300
pubmed: 32943724
Ann Oncol. 2022 Feb;33(2):129-142
pubmed: 34861373
J Clin Monit Comput. 2020 Jun;34(3):575-581
pubmed: 31264131